Please login to the form below

Not currently logged in
Email:
Password:

chronic cough

This page shows the latest chronic cough news and features for those working in and with pharma, biotech and healthcare.

Merck says Afferent’s chronic cough drug clears mid-stage trial

Merck says Afferent’s chronic cough drug clears mid-stage trial

MK-7264 reduces coughs per hour by 37%. Merck &Co's purchase of Afferent Pharma last year was all about a candidate drug for chronic cough - so it will be celebrating ... P2X3 receptors are thought to become over-activated in chronic cough, playing a

Latest news

  • Merck buys cough drug developer Afferent for $1.25bn Merck buys cough drug developer Afferent for $1.25bn

    Merck &Co has agreed a deal to buy California biopharma company Afferent Pharma, adding a drug candidate for chronic cough to its pipeline. ... In a statement Merck's R&F head Roger Perlmutter said chronic cough represents "an area of significant unmet

  • BMS takes option to buy fibrosis firm Galecto BMS takes option to buy fibrosis firm Galecto

    It takes the form of a progressive scarring of the lungs, leading to shortness of breath, cough and - in extreme cases - can lead to fatal complications such as heart failure. ... Genoa Pharmaceuticals has an inhaled version of pirfenidone in phase III

  • Pharma firms open up drug libraries to UK researchers Pharma firms open up drug libraries to UK researchers

    For example, clinical trials are now underway in Manchester to see whether an AZ drug designed originally to treat gastro-oesophageal reflux disease can be used to treat chronic cough.

  • GSK wins US approval for Seretide successor Breo Ellipta GSK wins US approval for Seretide successor Breo Ellipta

    FDA gives green light to COPD combination. GlaxoSmithKline's new long-term, once-daily, maintenance therapy for chronic obstructive pulmonary disease (COPD) has been approved in the US. ... COPD, whose symptoms can include chest tightness, chronic cough

  • Making the switch to OTC Making the switch to OTC

    We believe that patients should be the primary target of pharma customer loyalty strategies given the significant value of long-term relationships, particularly for patients suffering from chronic diseases. . ... worthwhile. Building customer loyalty

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    AF-219, a selective, non-narcotic, oral P2X3 antagonist, is currently in a phase 2b trial for the treatment of refractory, chronic cough and in a phase 2 trial in idiopathic ... licence, collaboration. 2, 560. Afferent Pharmaceuticals/ Merck &Co. AF-219,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics